For the treatment of EPI due to CF or other conditions
Zenpep® (pancrelipase) can help your patients absorb the fat they need1

ZENPEP offers dosing flexibility

ZENPEP has the widest range of dosing options, including the highest strength available—40,000 lipase units1

Find the appropriate per-meal ZENPEP dose for your patients with EPI due to cystic fibrosis or other conditions in 3 easy steps!

ZENPEP is designed for delayed release

ZENPEP has an enteric coating that minimizes degradation and targets enzyme release in the small intestine1

Minimizes destruction or inactivation in gastric acid1

Allows for delayed release of the enzymes until they are in the small intestine (at pH >5.5, based on in vivo studies)1

Not Actual Size

ZENPEP beads and microbeads are manufactured to be uniform in size and shape2

Patient Savings Program

Eligible patients may be able to start saving today with the ZENPEP Patient Savings Program*

Not Actual Card Image

*This offer is valid only for ZENPEP prescriptions. Eligible patients may pay as low as $0 per ZENPEP 30-day prescription fill; up to 12 fills. Check with pharmacist for copay discount. Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Program expires 4/30/19. Please see Non-CF Patient Support Program Terms, Conditions, and Eligibility Criteria at www.zenpepsupport.com. Please see CF Patient Support Program Terms, Conditions, and Eligibility Criteria at www.ZENPEPCFProgram.com.

If you are a healthcare professional licensed in Vermont, or a licensed healthcare professional who regularly practices in Vermont, Allergan corporate policy prohibits you from downloading, printing, or accepting the savings card.

ZENPEP combined insurance coverage through commerical and Medicare Part D is 94% for all dosage strengths, with unrestricted access2†

Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Fibrosing Colonopathy
  • Fibrosing colonopathy is a rare serious adverse reaction associated with high-dose use of pancreatic enzyme replacement.
  • Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
Potential for Irritation to Oral Mucosa
  • To avoid irritation of oral mucosa, care should be taken to ensure the ZENPEP capsule or its contents are not crushed, chewed, or retained in the mouth. ZENPEP may be added to a small amount of acidic soft food.
Potential for Risk of Hyperuricemia
  • Exercise caution when prescribing ZENPEP to patients with gout, renal impairment or hyperuricemia.
Potential Viral Exposure from the Product Source
  • There is theoretical risk of viral transmission with all pancreatic enzyme products, including ZENPEP; however, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.
Allergic Reactions
  • Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase).
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
 Adverse Reactions
  • The most common adverse events (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, cough, decreased weight, early satiety, and contusion.
Additional Important Safety Information
  • ZENPEP is not interchangeable with any other pancrelipase product.
  • Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.
INDICATIONS AND USAGE

ZENPEP® (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

References

1. ZENPEP [package insert]. Irvine, CA: Allergan USA, Inc.; March 2017. 2. Data on file. Allergan Pharmaceuticals.

IMPORTANT SAFETY INFORMATION and INDICATION More Less
Warnings and Precautions
Fibrosing Colonopathy
  • Fibrosing colonopathy is a rare serious adverse reaction associated with high-dose use of pancreatic enzyme replacement.
  • Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
Potential for Irritation to Oral Mucosa
  • To avoid irritation of oral mucosa, care should be taken to ensure the ZENPEP capsule or its contents are not crushed, chewed, or retained in the mouth. ZENPEP may be added to a small amount of acidic soft food.
Potential for Risk of Hyperuricemia
  • Exercise caution when prescribing ZENPEP to patients with gout, renal impairment or hyperuricemia.
Potential Viral Exposure from the Product Source
  • There is theoretical risk of viral transmission with all pancreatic enzyme products, including ZENPEP; however, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.
Allergic Reactions
  • Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase).
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
 Adverse Reactions
  • The most common adverse events (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, cough, decreased weight, early satiety, and contusion.
Additional Important Safety Information
  • ZENPEP is not interchangeable with any other pancrelipase product.
  • Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.
INDICATIONS AND USAGE

ZENPEP® (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.